Skip to main content
. Author manuscript; available in PMC: 2018 Jun 28.
Published in final edited form as: Cancer Lett. 2017 Mar 14;396:145–154. doi: 10.1016/j.canlet.2017.03.011

Figure 3. Effect of regorafenib and paclitaxel on the growth of SW620 tumors in nude athymic mice.

Figure 3

(A) The images of excised SW620 tumors implanted subcutaneously in athymic NCR nude mice (n = 8) that were treated with vehicle, regorafenib, paclitaxel, or the combination of regorafenib and paclitaxel, at the end of the 18-day treatment period. (B) The changes in tumor volume over time following the implantation. Data points represent the mean tumor volume for each treatment group (n = 8). Error bars, SEM. *P < 0.05 versus the vehicle group; #P < 0.05 versus the paclitaxel group; one-way ANOVA with Bonferroni post-test. (C) The mean weight (n = 8) of the excised SW620 tumors from the mice treated with vehicle, regorafenib, paclitaxel, or the combination of regorafenib and paclitaxel, at the end of the 18-day treatment period. Error bars, SEM. *P < 0.05 versus the vehicle group; #P < 0.05 versus the paclitaxel group; one-way ANOVA with Bonferroni post-test.